logo
‘Are there nuts in this?' She left the nightclub in an ambulance, despite warning the waiter of her allergy

‘Are there nuts in this?' She left the nightclub in an ambulance, despite warning the waiter of her allergy

Toronto Star12-05-2025

The group of 10 friends had gathered at a popular nightclub on Dundas Street West to celebrate a special birthday with dinner and salsa dancing.
But a small bite of banana cake brought the party to an abrupt end.
'Are there nuts in this!?' Sabrina Grozdanovski asked, turning to her friends in shock.
'It's happening,' she exclaimed.
With her lips and throat swelling, Grozdanovski ran from the private dining area of the Lula Lounge and out its front doors to call 911 while her friends tried to get a straight answer from the kitchen about the cake's ingredients.
ARTICLE CONTINUES BELOW
As paramedics loaded the 24-year-old woman into an ambulance, the chef insisted the cake wasn't to blame.
'It was terrifying,' says Grozdanovski.
The problem: She said she was allergic to 'all nuts'
When the group placed their dinner orders the night of March 15, Grozdanovski noted her severe allergy to 'all nuts,' a detail she said the waiter typed into an electronic tablet.
Grozdanovski said she's had the nut allergy her whole life, but hasn't had a reaction since childhood. When the wait staff told her the chef was adamant the dessert contained no nuts, she didn't know whether to take her Epi pen and waited for paramedics to administer it.
She thought she had detected a crunchiness in her small bite. While she waited outside for an ambulance, her friends forked apart the cake looking for clues. They saw what looked like chopped nuts but the chef insisted it wasn't possible.
More than an hour after the group left, a senior manager emailed one of Grozdanovski's friends a pdf of the cake's ingredients list, confirming the chef's serious error — the cake contained walnuts.
'Please let me know how this situation develops,' he wrote.
Grozdanovski reached out to Lula Lounge after her release from hospital where she received more medicine to counter her allergic reaction and IV fluids.
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
She and a friend who accompanied her to hospital took an Uber back home to Whitby.
'We are horrified that this has happened,' Tracy Jenkins, a long-time Lula senior manager wrote by email to Grozdanovski the next night. 'We will get back to you asap with a full account of how we intend to address this issue to make sure that it never happens again.'
A few days later, Jenkins emailed Grozdanovski, noting her team was preparing a 'full report on the actions we have taken and will continue to follow through on,' including a 'review of our allergy plan.'
She said she would reach out again before the end of the week, but never did.
'I've spent the past two months being gaslit, ignored, and denied basic accountability from a place that should've known better,' said Grozdanovski, who is seeking answers about the venue's allergy protocols and financial compensation.
Grozdanovski followed up with Lula several times after Jenkins had emailed, but no one reached out.
'I gave Lula every opportunity to handle this privately, with dignity,' she said. 'I reached out professionally. I set deadlines. I was transparent. I was more kind and understanding than I should've been. They dragged this out for two months — then went silent. Meanwhile, they continue to post about weekend parties and receive good reviews like nothing happened.'
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
The Star steps in: 'We messed up,' says co-owner
So what did happen?
I reached out to Lula Lounge looking for answers.
Jose Ortega, one of the venue's co-owners, called me immediately on What's App from Spain.
'Without a doubt, we messed up,' he said. 'Our dessert person quit that week,' so the restaurant ordered prepackaged desserts to fill the gap.
The banana cake was 'literally introduced that day,' he said.
The chef, Ortega said, 'didn't bother to check' (the cake box's label.) He just made an assumption he shouldn't have made. He should have said, 'I don't know.' It was unprofessional.'
Ortega confirmed 'a manager went into the store room to find the packaging because nobody was getting a satisfactory answer from the chef.'
Lula Lounge fired the chef and took banana cake off the menu.
The Advocate
Baby on standby no isolated incident: Several Star readers say they were separated from kids on flights too
'On at least six occasions, Air Canada did the exact same thing and separated us at the last
He says Lula has since created printed and digital files of the ingredients used in every dish on its menu, which he calls 'The Bible.'
The kitchen has also implemented a new rule, he said.
'Nothing gets switched out randomly if an ingredient is not available,' he said. 'If we can't get the ingredient, (the dish) goes off the menu.'
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
Grozdanovski had initially ordered a different dessert that night but was told it wasn't available. She selected the banana cake based on its menu description and the wait staff's assurances it was nut free.
As she ran outside to catch her breath and call an ambulance, Grozdanovski said none of the staff came to see how she was doing.
Ortega said he wasn't in the venue that night and can't speak to the staff's response to the medical emergency.
'I would be surprised if they were callous about it,' he said.
The resolution: Restaurant offers $3,000
While Grozdanovski was en route to hospital with one friend, the others stayed behind to sort out the allergen question and final bills.
They were taken aback, Grozdanovski said, to find the restaurant was going to charge them and had added a 20 per cent gratuity to their orders.
After some debate, the floor manager waived the cost of their meals.
Grozdanovski also wanted Lula to cover the costs of her ambulance ride to hospital, the Uber ride home to Whitby and other expenses that she and her friends incurred for the night, an amount she said totalled $3,000.
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
'We weren't sure where that came from,' Ortega said. Jenkins initially asked Grozdanovski to provide receipts, a request she found insulting.
'It's such a headache to have to deal with this,' she said. 'I don't want to bother my friends for this, squeezing them for all the screenshots (of their receipts).'
Ortega noted that Grozdanovski and her friends have left a trail of one-star reviews on Google and Open Table detailing their experience that is hurting the business. He would like it to stop.
Lula's lawyer, Ortega said last Thursday, 'will be reaching out to her directly this afternoon to offer her $3,000.'
No receipts required.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Brazilian leader Lula hospitalized with inner ear ailment, then released
Brazilian leader Lula hospitalized with inner ear ailment, then released

CTV News

time27-05-2025

  • CTV News

Brazilian leader Lula hospitalized with inner ear ailment, then released

Brazil's President Luiz Inacio Lula da Silva attends a joint press conference with Chinese President Xi Jinping (not pictured) at the Great Hall of the People in Beijing, China, Tuesday, May 13, 2025. (Tingshu Wang/Pool Photo via AP) RIO DE JANEIRO — Brazil's President Luiz Inácio Lula da Silva was diagnosed with labyrinthitis Monday after suffering from vertigo, hospital officials said. The 79-year-old leftist leader has already returned to the country's presidential residence, where he is resting. The Sirio-Libanes Hospital said in a statement that Lula underwent imaging and blood tests, and its results came within normal limits. Labyrinthitis is an inflammation of the labyrinth in the inner ear, which is responsible for hearing and balance. The health scare adds to Lula's recent medical worries, which are also part of his allies' concerns ahead of his likely bid for reelection next year. The most serious is a fall he had in the bathroom of the presidential residence in Brasília on Oct. 19. Almost two months later, he was transferred to São Paulo for surgery after suffering headaches caused by new a bleeding in his head. He was discharged Dec. 15.

‘Are there nuts in this?' She left the nightclub in an ambulance, despite warning the waiter of her allergy
‘Are there nuts in this?' She left the nightclub in an ambulance, despite warning the waiter of her allergy

Toronto Star

time12-05-2025

  • Toronto Star

‘Are there nuts in this?' She left the nightclub in an ambulance, despite warning the waiter of her allergy

The group of 10 friends had gathered at a popular nightclub on Dundas Street West to celebrate a special birthday with dinner and salsa dancing. But a small bite of banana cake brought the party to an abrupt end. 'Are there nuts in this!?' Sabrina Grozdanovski asked, turning to her friends in shock. 'It's happening,' she exclaimed. With her lips and throat swelling, Grozdanovski ran from the private dining area of the Lula Lounge and out its front doors to call 911 while her friends tried to get a straight answer from the kitchen about the cake's ingredients. ARTICLE CONTINUES BELOW As paramedics loaded the 24-year-old woman into an ambulance, the chef insisted the cake wasn't to blame. 'It was terrifying,' says Grozdanovski. The problem: She said she was allergic to 'all nuts' When the group placed their dinner orders the night of March 15, Grozdanovski noted her severe allergy to 'all nuts,' a detail she said the waiter typed into an electronic tablet. Grozdanovski said she's had the nut allergy her whole life, but hasn't had a reaction since childhood. When the wait staff told her the chef was adamant the dessert contained no nuts, she didn't know whether to take her Epi pen and waited for paramedics to administer it. She thought she had detected a crunchiness in her small bite. While she waited outside for an ambulance, her friends forked apart the cake looking for clues. They saw what looked like chopped nuts but the chef insisted it wasn't possible. More than an hour after the group left, a senior manager emailed one of Grozdanovski's friends a pdf of the cake's ingredients list, confirming the chef's serious error — the cake contained walnuts. 'Please let me know how this situation develops,' he wrote. Grozdanovski reached out to Lula Lounge after her release from hospital where she received more medicine to counter her allergic reaction and IV fluids. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW She and a friend who accompanied her to hospital took an Uber back home to Whitby. 'We are horrified that this has happened,' Tracy Jenkins, a long-time Lula senior manager wrote by email to Grozdanovski the next night. 'We will get back to you asap with a full account of how we intend to address this issue to make sure that it never happens again.' A few days later, Jenkins emailed Grozdanovski, noting her team was preparing a 'full report on the actions we have taken and will continue to follow through on,' including a 'review of our allergy plan.' She said she would reach out again before the end of the week, but never did. 'I've spent the past two months being gaslit, ignored, and denied basic accountability from a place that should've known better,' said Grozdanovski, who is seeking answers about the venue's allergy protocols and financial compensation. Grozdanovski followed up with Lula several times after Jenkins had emailed, but no one reached out. 'I gave Lula every opportunity to handle this privately, with dignity,' she said. 'I reached out professionally. I set deadlines. I was transparent. I was more kind and understanding than I should've been. They dragged this out for two months — then went silent. Meanwhile, they continue to post about weekend parties and receive good reviews like nothing happened.' ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW The Star steps in: 'We messed up,' says co-owner So what did happen? I reached out to Lula Lounge looking for answers. Jose Ortega, one of the venue's co-owners, called me immediately on What's App from Spain. 'Without a doubt, we messed up,' he said. 'Our dessert person quit that week,' so the restaurant ordered prepackaged desserts to fill the gap. The banana cake was 'literally introduced that day,' he said. The chef, Ortega said, 'didn't bother to check' (the cake box's label.) He just made an assumption he shouldn't have made. He should have said, 'I don't know.' It was unprofessional.' Ortega confirmed 'a manager went into the store room to find the packaging because nobody was getting a satisfactory answer from the chef.' Lula Lounge fired the chef and took banana cake off the menu. The Advocate Baby on standby no isolated incident: Several Star readers say they were separated from kids on flights too 'On at least six occasions, Air Canada did the exact same thing and separated us at the last He says Lula has since created printed and digital files of the ingredients used in every dish on its menu, which he calls 'The Bible.' The kitchen has also implemented a new rule, he said. 'Nothing gets switched out randomly if an ingredient is not available,' he said. 'If we can't get the ingredient, (the dish) goes off the menu.' ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Grozdanovski had initially ordered a different dessert that night but was told it wasn't available. She selected the banana cake based on its menu description and the wait staff's assurances it was nut free. As she ran outside to catch her breath and call an ambulance, Grozdanovski said none of the staff came to see how she was doing. Ortega said he wasn't in the venue that night and can't speak to the staff's response to the medical emergency. 'I would be surprised if they were callous about it,' he said. The resolution: Restaurant offers $3,000 While Grozdanovski was en route to hospital with one friend, the others stayed behind to sort out the allergen question and final bills. They were taken aback, Grozdanovski said, to find the restaurant was going to charge them and had added a 20 per cent gratuity to their orders. After some debate, the floor manager waived the cost of their meals. Grozdanovski also wanted Lula to cover the costs of her ambulance ride to hospital, the Uber ride home to Whitby and other expenses that she and her friends incurred for the night, an amount she said totalled $3,000. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW 'We weren't sure where that came from,' Ortega said. Jenkins initially asked Grozdanovski to provide receipts, a request she found insulting. 'It's such a headache to have to deal with this,' she said. 'I don't want to bother my friends for this, squeezing them for all the screenshots (of their receipts).' Ortega noted that Grozdanovski and her friends have left a trail of one-star reviews on Google and Open Table detailing their experience that is hurting the business. He would like it to stop. Lula's lawyer, Ortega said last Thursday, 'will be reaching out to her directly this afternoon to offer her $3,000.' No receipts required.

Exocrine Pancreatic Insufficiency Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, and Companies by DelveInsight
Exocrine Pancreatic Insufficiency Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, and Companies by DelveInsight

Globe and Mail

time16-01-2025

  • Globe and Mail

Exocrine Pancreatic Insufficiency Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, and Companies by DelveInsight

Exocrine Pancreatic Insufficiency Companies are AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and many others. (Albany, USA) DelveInsight's "Exocrine Pancreatic Insufficiency Market Insight, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of exocrine pancreatic insufficiency, historical and forecasted epidemiology as well as the exocrine pancreatic insufficiency market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The Exocrine Pancreatic Insufficiency market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Exocrine Pancreatic Insufficiency market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Exocrine Pancreatic Insufficiency treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Exocrine Pancreatic Insufficiency market. Explore the intricate details of the Exocrine Pancreatic Insufficiency Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Exocrine Pancreatic Insufficiency Market Forecast. Click here to stay ahead in healthcare innovation @ Exocrine Pancreatic Insufficiency Market Size Key Takeaways from the Exocrine Pancreatic Insufficiency Market Report November 2023:- Andrew Hendifar, MD- Pancreatic-enzyme Replacement Therapy With Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency. According to a study conducted by Nieto et al. (2016), several prevalence studies and the relation of EPI in both types of diabetes show a wide range, being higher in Type I diabetes with a prevalence of 25–74% versus a 28– 54% in type II diabetics. According to Jiuang et al. (2023), the prevalence of EPI in newly diagnosed Crohn's Disease (CD) patients ranges from 10.5% to 46.5%, with a pooled prevalence of 26.2% (95% CI 8.43–43.92%). In CD patients on a gluten-free diet (GFD), the rate of EPI ranges from 1.9% to 18.2%. The total diagnosed prevalent cases of EPI in the US in 2023 were found to be highest among the 7MM. About ~80% of patients suffering from Cystic Fibrosis and Schwachman–Diamond Syndrom developed EPI in the US in the year 2023. In the United States the causative indication accounting for the highest cases of EPI were Celiac disease and Type II diabetes comprising about ~2,419,000 and ~32,205,000 cases respectively among the other causative diseases like Mild Acute Pancreatitis, Moderate to Severe Acute Pancreatitis Chronic Pancreatitis, Celiac Disease, Cystic Fibrosis, Crohn's Disease, Diabetes (Type I and II) and others The leading Exocrine Pancreatic Insufficiency Companies such as AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and many others. Promising Exocrine Pancreatic Insufficiency Therapies such as PERTZYE (pancrelipase), CREON (pancrelipase)/LIPACREON, ZENPEP (pancrelipase), .PANCREAZE (pancrelipase), VIOKACE (pancrelipase), and others. Delve deep into the Exocrine Pancreatic Insufficiency Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Exocrine Pancreatic Insufficiency Market Forecast. Click here to shape the future @ Exocrine Pancreatic Insufficiency Epidemiology Insights Exocrine Pancreatic Insufficiency Overview Exocrine pancreatic insufficiency (EPI) is a condition caused by reduced or inappropriate secretion or activity of pancreatic juice and its digestive enzymes, pancreatic lipase in particular. EPI can result in clinical manifestation such as steatorrhea, weight loss, and biochemical alterations related to lipids and liposoluble micronutrients malabsorption and maldigestion. Exocrine Pancreatic Insufficiency Epidemiology Insights Exocrine Pancreatic Insufficiency Prevalence in the US Exocrine Pancreatic Insufficiency Prevalence of Causative Indications Exocrine Pancreatic Insufficiency Diagnosed and Treatable Cases Navigate the complexities of the Exocrine Pancreatic Insufficiency Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Exocrine Pancreatic Insufficiency Market Forecast. Click here to get more insights @ Exocrine Pancreatic Insufficiency Treatment Market Exocrine Pancreatic Insufficiency Treatment Market Landscape The Exocrine Pancreatic Insufficiency treatment primarily focuses on supplementing the deficient pancreatic enzymes and managing the underlying causes to improve digestion and nutrient absorption. Effective management of EPI involves a combination of enzyme replacement therapy, dietary modifications, addressing underlying causes, and lifestyle changes. These treatments aim to improve digestive function, enhance nutrient absorption, and alleviate symptoms to improve the patient's quality of life. Exocrine Pancreatic Insufficiency Market Factors Key factors contributing to the positive Exocrine Pancreatic Insufficiency market growth include the increasing prevalence of conditions like cystic fibrosis and chronic pancreatitis, advancements in pancreatic enzyme replacement therapy (PERT), and rising awareness and early diagnosis of EPI. Additionally, an aging population and increased healthcare expenditure enhance market demand. Regulatory approvals and investment in research and development also drive Exocrine Pancreatic Insufficiency market growth. Unlock insights into the Exocrine Pancreatic Insufficiency Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Exocrine Pancreatic Insufficiency Market Forecast. Click here @ Exocrine Pancreatic Insufficiency Market Drivers and Barriers Exocrine Pancreatic Insufficiency Marketed Drugs PERTZYE: Digestive Care PERTZYE is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases. In July 2012, PERTZYE was approved by the US FDA in patients with exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Further, in October 2016, the drug received FDA approval for an infant-specific dose of PERTZYE in a 4,000 USP lipase units capsule. The new capsule strength will enable guideline-recommended dosing and administration of PERTZYE for infants (up to 12 months) with exocrine pancreatic insufficiency. It is a pancreatic enzyme preparation consisting of a combination of lipases, proteases, and amylases and is an extract derived from porcine pancreatic glands. In May 2013, CREON received the US FDA approval for the commercial availability of a new, higher-dose variant of CREON delayed-release capsules to treat patients with EPI due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions. In April 2011, CREON was approved in Japan under the brand name LIPACREON. Exocrine Pancreatic Insufficiency Emerging Drugs FW-EPI (adrulipase): First Wave Biopharma FW-EPI is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. It is derived from the Yarrowia lipolytica yeast lipase and is designed to break up fat molecules in the digestive tract of exocrine pancreatic insufficiency patients so that they can be absorbed as nutrients. In developing adrulipase, First Wave is seeking to provide cystic fibrosis and chronic pancreatitis patients with a safe and effective therapy to control exocrine pancreatic insufficiency that is non-animal derived, offers the potential to dramatically reduce their daily pill burden, and can be manufactured on demand at high volumes safely and with a high degree of reproducibility. First Wave is developing adrulipase as a monotherapy and in combination with PERT. ANG003: Anagram Therapeutics ANG003 is a novel broadspectrum orally delivered enzyme replacement therapy for the treatment of malabsorption and exocrine pancreatic insufficiency. The drug is currently in Phase I trial for adult subjects with CF-related EPI. Exocrine Pancreatic Insufficiency Market Outlook The treatment landscape of exocrine pancreatic insufficiency majorly includes pancreatic enzyme replacement therapy, lifestyle modifications (e.g., avoidance of fatty foods, limitation of alcohol intake, cessation of smoking, and consumption of a well-balanced diet), and vitamin supplementation (primarily the fat-soluble vitamins A, D, E, and K). PERT is the first-line therapeutic mainstay that is prescribed to patients. The pancreatic enzyme products used for PERT are extracts of porcine pancreas that contain all three pancreatic enzymes (i.e., amylase, protease, and lipase) in varying proportions. However, it is lipase that plays a paramount role in therapy. Pharmacological therapies are the mainstay treatment option followed by patients with exocrine pancreatic insufficiency. The market of exocrine pancreatic insufficiency includes the use of the drugs either as monotherapy and are not interchangeable. There are several approved drugs in the market of different classes. The following PEPs have been approved by the FDA for the treatment of maldigestion in patients whose bodies do not produce sufficient pancreatic enzymes: CREON, PANCREAZE, PERTZYE, VIOKACE, and ZENPEP. Some medicines are needed to treat pain. Scope of the Exocrine Pancreatic Insufficiency Market Report Coverage- 7MM Exocrine Pancreatic Insufficiency Companies- AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and many others. Exocrine Pancreatic Insufficiency Therapies- PERTZYE (pancrelipase), CREON (pancrelipase)/LIPACREON, ZENPEP (pancrelipase), .PANCREAZE (pancrelipase), VIOKACE (pancrelipase), and others. Exocrine Pancreatic Insufficiency Market Dynamics: Exocrine Pancreatic Insufficiency Market drivers and Exocrine Pancreatic Insufficiency Market Barriers Exocrine Pancreatic Insufficiency Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Exocrine Pancreatic Insufficiency Unmet Needs, KOL's views, Analyst's views, Exocrine Pancreatic Insufficiency Market Access and Reimbursement Gain a strategic edge in the Exocrine Pancreatic Insufficiency Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Exocrine Pancreatic Insufficiency Market Forecast. Click here to lead in advancements @ Exocrine Pancreatic Insufficiency Clinical Trials Assessment Table of Content 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Exocrine Pancreatic Insufficiency (EPI) Market Overview at a Glance 5. Key Events 6. Exocrine Pancreatic Insufficiency Epidemiology and Market Forecast Methodology 7. Disease Background and Overview 8. Exocrine Pancreatic Insufficiency Epidemiology and Patient Population 9. Exocrine Pancreatic Insufficiency Patient Journey 10. Marketed Exocrine Pancreatic Insufficiency Products 11. Emerging Exocrine Pancreatic Insufficiency Therapies 12 Exocrine Pancreatic Insufficiency Market: Seven Major Market Analysis 13. Exocrine Pancreatic Insufficiency Unmet Needs 14. Exocrine Pancreatic Insufficiency SWOT Analysis 15. Exocrine Pancreatic Insufficiency KOL Views 16. Exocrine Pancreatic Insufficiency Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store